GUANGZHOU, China, Aug.

GUANGZHOU, China, July 8, 2011 /PRNewswire-Asia/ -- China Medicine Corporation (Other OTC: CHME) (the "Company"), a leading manufacturer, developer and distributor of Western pharmaceuticals, traditional Chinese medicines ("TCM"), and other health products in the People's Republic of China, today announced that the Board of Directors (the "Board") of China Medicine Corporation, after consultation with and upon the recommendation of the management of the Company and the Audit Committee of the Board (the "Audit Committee"), concluded that the Company's previously issued financial statements contained in the Company's Annual Report on Form 10-K for the fiscal years ended December 31, 2006 and 2007, and the Quarterly Reports on Form 10-Q for the periods within the fiscal years 2006 and 2007 (collectively, "the previously issued financial statements") should no longer be relied upon.

GUANGZHOU, China, March 23, 2011 /PRNewswire-Asia/ -- China Medicine Corporation (OTC Bulletin Board: CHME) (the "Company"), a leading manufacturer, developer and distributor of Western pharmaceuticals, traditional Chinese medicines ("TCM"), and other health products in the People's Republic of China, today announced that it has filed with the United States Securities and Exchange Commission 1) a Current Report on Form 8-K to disclose that its previously issued financial statements should not be relied upon, and 2) a Form 12b-25 Notification of Late Filing for its Annual Report on Form 10-K for the year ended December 31, 2010.

GUANGZHOU, China, March 23, 2011 /PRNewswire-Asia/ -- China Medicine Corporation (OTC Bulletin Board: CHME) (the "Company"), a leading manufacturer, developer and distributor of Western pharmaceuticals, traditional Chinese medicines ("TCM"), and other health products in the People's Republic of China, today announced that the Company's Board of Directors authorized a voluntary withdrawal of the Company's application for listing its common stock on the Nasdaq Global Market. On March 9, 2010, the Company announced its intention to list on Nasdaq in order to broaden its shareholder base, improve trading liquidity and raise the Company's profile in the investment community.

GUANGZHOU, China, March 3, 2011 /PRNewswire-Asia-FirstCall/ -- China Medicine Corporation (OTC Bulletin Board: CHME) (the "Company"), a leading manufacturer, developer and distributor of Western pharmaceuticals, traditional Chinese medicines ("TCM"), and other health products in the People's Republic of China, today announced that the Board of Directors (the "Board") adopted, subject to stockholder approval, the 2011 Long-Term Incentive Plan (the "2011 Incentive Plan"), covering a maximum of 4 million shares of common stock, par value $0.0001 per share, of the Company (the "Common Stock").